The month ahead: February’s upcoming events
Approval decisions await Ono and SpringWorks, while key data approach for Pfizer and Arvinas’s SERD.
AstraZeneca doubles down on GPC3
The company takes its T-cell engager into the clinic, just as Roche and Sanofi exit.
FDA red and green lights: January 2025
AstraZeneca bags three of the month’s four oncology approvals.
Zentalis doubles down on Wee1
But the new focus on a predictive biomarker could cut the market in half.
NextCure joins the B7-H4 brigade
Meanwhile, Olema’s KAT6 inhibitor will take on rival projects from Pfizer and Menarini.
